シングルセルマルチオミクスのための瞬間凍結肝臓組織からの核の単離

Executive Industry Relevance

Single-nucleus isolation from flash-frozen liver tissue enables high-resolution multiomic profiling of hepatic cell populations, supporting mechanistic de-risking and target validation in complex disease models. This protocol preserves cell-type diversity and ploidy, facilitating unbiased discovery of transcriptional and epigenetic regulators relevant to metabolic and toxicological pathways. Its compatibility with archived biobank samples enhances translational continuity and portfolio flexibility for liver-focused drug discovery programs.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of hepatic cell heterogeneity and zonation at single-cell resolution.
• Supports identification of disease-relevant transcription factors and pathway regulators.
• Facilitates mechanistic de-risking by preserving all major liver cell types and ploidy states.
• Provides high-confidence data for functional target validation in metabolic and toxicological research.

Screening & Assay Development

• Generates high-quality nuclei suspensions suitable for standardized single-nucleus RNA-seq and ATAC-seq workflows.
• Ensures reproducibility and scalability across healthy and diseased, human and animal liver samples.
• Enables robust preparation of samples for downstream multiomic screening platforms.
• Supports quantitative assessment of gene expression and chromatin accessibility for compound evaluation.

Translational & Preclinical Research

• Aligns with translational biomarker discovery by enabling analysis of archived human and preclinical liver tissues.
• Maintains continuity from discovery through preclinical validation by supporting multi-species sample processing.
• Reduces risk of sample bias, supporting risk-adjusted advancement decisions in liver disease portfolios.
• Facilitates identification of conserved and species-specific regulatory mechanisms.

Pipeline & Workflow Integration

This nuclei isolation protocol integrates into the discovery-to-preclinical continuum, enabling single-cell multiomics from archived and fresh liver samples for target validation, lead identification, and translational research.

• Discovery Biology: Supports hypothesis testing and pathway clarification by enabling unbiased profiling of hepatic cell populations.
• Screening: Delivers reproducible, quantitative nuclei preparations for high-throughput omics assays.
• Analytics: Provides robust readouts for gene expression, chromatin accessibility, and ploidy analysis across conditions.
• Translational Research: Enables biomarker alignment and mechanistic studies using biobanked human and animal tissues.
• Enterprise Reuse: Offers a standardized, scalable protocol adaptable across liver disease models and sample types.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in liver biology studies.
• Operational Value: Enhances standardization, reproducibility, and scalability for multiomic workflows.
• Strategic Value: Improves go/no-go decisions and capital efficiency by enabling robust target and biomarker validation.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of liver disease programs.

Implementation Considerations

• Requires expertise in tissue handling, nuclei isolation, and single-cell omics technologies.
• Needs access to density gradient centrifugation, flow cytometry, and sequencing infrastructure.
• Demands cross-team standardization for sample processing and data analysis.
• Adaptable to various species and disease models with attention to tissue quality and storage conditions.
• Careful homogenization and handling are critical to preserve nuclear integrity and minimize technical artifacts.

Biopharma FAQs